Tekcapital – its shares are at far too steep a discount to value

Almost a year ago the shares of Tekcapital (LON:TEK) were trading at 34p, they have since then fallen by over 70% to the current 9.75p.

It declares that its investment objective is to achieve long-term growth of net assets and returns on invested capital through the commercialisation of university discoveries that can make a positive impact on people’s lives. 

Considering that every move that the company’s management has made in the last year has done nothing but improve its overall profile – the market appears to be truly undervaluing this investor in intellectual property.

Perhaps the Interim Results due to be announced later this month will prove to be the precursor of investors taking a very much more positive view of the company’s business, its structure and its corporate prospects going forward.

The Business

Identifying and capitalising upon a selection of projects that have been created by some of the world’s leading universities is just what the company is all about.

It has a global network of contacts, through which it gleans thousands of patents and schemes originating from the billions of pounds spent each year upon technology research.

Spanning some 160 countries around the world, its network includes some 4,500 research bodies and universities.

Founder Dr Clifford Gross and his team sift through patent applications, some 100,000 of which are filed each year.

Tekcapital researches and identifies the potential viability of commercialising such prospects and selects several for further analysis.

It has a panel of over 60 industry experts from various fields, using their knowledge to delve deeper into such prospective investments, and then evaluate development candidates.

Apart from offering this ability as a service to hundreds of its universities, research institutions and business subscribers, it also helps to provide them with technology transfer services as they look to commercialise new disruptive technologies.

More importantly, though, the company also selects several for its own investment.

The group creates its value by investing in new, university-developed discoveries that it believes can enhance people’s lives.

It considers that when you couple commercialisation-ready, compelling university intellectual property with visionary individuals, then vibrant companies will emerge that could produce strong returns on invested capital.

Those eventual investments are then progressed towards their own IPOs, giving them the opportunity to raise further development capital.

In due course, the company expects each investment to outperform its sector, providing it with the opportunity to exit part or all of its investment, which in turn gives the group the ability to return a portion of the proceeds as a ‘special dividend’ to its shareholders.

It has an ability to transform university discoveries into valuable, much-needed products.

The value of its investment portfolio is very much more than double the current market capitalisation, while events due soon could see that discount widen even more.

The Portfolio

Currently the £18m capitalised group has a portfolio of patent interests. Its business model is to take the pick of those researched situations, invest in them, team it up with a ‘star-power’ management with both experience and vision, then progress it forward to an eventual fund-raising, further development and success, before part or total exit of its equity position.

Its main portfolio constituents are:

Lucyd Limitedwww.lucyd.co 70% owned

Lucyd is seeking to Upgrade Your Eyewear® by developing and selling designer tech-enhanced eyewear at affordable prices.

It has recently introduced the world’s first smart eyewear with ChatGPT.

Lucyd’s 58% owned US operating subsidiary, Innovative Eyewear Inc (NASDAQ: LUCY), was the first company to deliver prescription glasses with Bluetooth® technology in 2019.

Its eyeglass frames help the wearer stay connected safely and conveniently, by enabling many common smartphone tasks to be performed handsfree with Bluetooth® and voice assistants.

Guident www.guident.co 100% owned

Guident Limited is developing remote monitoring and control software to improve the safety of autonomous vehicles and land-based delivery devices.

Its software will incorporate artificial intelligence and advanced network technologies to minimise signal latency and improve the safety of autonomous vehicles.

Developing intellectual property and software solutions to increase the safety and efficiency of electric and autonomous vehicles.

MicroSalt Ltd www.microsaltinc.com 97% owned

This company manufactures MicroSalt®, which is a new, patented, all natural, non-GMO, Kosher, low-sodium salt, that tastes great and has approximately half of the sodium of regular table salt.

Belluscura Plc (LON:BELL)  www.belluscura.com 12% owned

Belluscura is a respiratory medical device company that has developed and launched an improved portable oxygen concentrator (POC) to provide on-the-go supplemental O2.

The company believes its product is the first FDA cleared, modular POC with a user-replaceable filter cartridge.

Belluscura aims to make POCs more affordable to those who need them.

Latest Results – 26th May

Understandably the group’s net assets eased back in the year to end December 2022, due to the difficult equity markets in the period to $57.8m ($68.1m), leaving its net asset value per share at $0.38 ($0.48).

The company’s Portfolio valuation at the year-end was $54.9m ($62.5m).

The impact of a net unrealised fair value reduction of $11.0m, created a total loss after tax of $12.7m ($26.4m profit).

Commenting upon the current year Outlook Dr Clifford Gross stated that:

“We are enthusiastic about the development of Tekcapital’s portfolio companies, their performance to-date and their prospects to significantly expand in 2023.

The Board is confident that continued investment in our non-quoted portfolio companies remains the right approach for potential long-term value creation.

Additionally, we are currently exploring additional funding for our non-quoted, portfolio companies, to accelerate growth for these companies.”

The Equity

There are some 178.2m shares in issue.

Larger holders include Clifford Gross, Chmn, (4.86%), James Knight (4.28%), Nigel Wray (4.06%), Elie Dangoor (3.30%) and Edale Capital (2.18%).

Analyst Opinion – the shares are a Buy

Brokers SP Angel rate the group’s shares as a Buy.

Their analysts note that the company’s net asset value, as at TEK financials on 31st May, were £46.8m.

However, that was before £4.25m of new cash raised in February and April of this year takes it up to £51.07m.

The brokers stated that there has been a great deal of commercial activity at each of the portfolio companies since year-end, creating additional upside in the potential return to investors over the reported NAV.

Conclusion – far too steep a discount to its value

This innovative investment company’s shares should not be trading at such a significant discount to its net asset value.

Upon SP Angel’s estimates that gives an NAV of 28.66p per share, giving a 66% discount to value, with the shares currently trading at only 9.75p.

Even at a 50% discount, which is also a steep discount, the shares would then be trading at nearly 14.5p each, which offers patient investors a very attractive upside.

FTSE 100 edges higher despite soft Chinese data, US CPI eyed

The FTSE 100 crept higher on Monday as investors shook off more downbeat Chinese economic data and looked forward to US CPI inflation data due to be released on Wednesday.

The FTSE 100 was 0.45% higher at 7,290 at the time of writing.

Chinese producer prices sank 5.4% in June, the worst decline since 2015, and piled further pressure on Chinese authorities to take additional steps to stimulate their economy.

“The continued loss of power in the Chinese economy is concerning investors, with consumer prices flatlining. The downbeat data comes ahead of the key inflation snapshot in the United States on Wednesday, which could determine how long the monetary squeeze will continue,” said Susannah Streeter, head of money and markets, Hargreaves Lansdown.

“While inflation shows signs of stubbornness in other economies, disinflationary forces are at work in China, which risk tipping the world’s second largest economy into a deflation scenario.”

The frequency of poor Chinese economic data releases has increased recently, and many investors have positioned for imminent easing. There is an argument that additional Chinese stimulus is already priced into stocks, and the immediate market reaction to new measures will be muted.

The FTSE 100’s miners were little changed on Monday.

US CPI

Inflation remains the overarching theme in markets, and investors will closely watch Wednesday’s US CPI print for any hint of central banks’ next moves.

“Last week’s big pullback in global equities has hurt investor sentiment and triggered a ‘wait and see’ approach among many people who have become nervous about deploying more money in the markets until there is more clarity on the next central bank interest rate decisions,” said Russ Mould, investment director at AJ Bell.

“It seems likely the Federal Reserve, ECB and Bank of England will continue to raise rates in the fight against inflation. Labour markets are holding up better than expected and plenty of businesses continue to grow profits. However, the more rates go up, the bigger the risk of a hard landing – reaching the point where a lot more consumers and businesses cannot cope with the higher cost of borrowing and we suddenly see a slump in the economy.”

DWF bid approach

0

Legal services provider DWF (LON: DWF) is the best performing company on the Main Market following a bid approach by Inflexion Private Equity Partners. The offer is 97p/share and the market price jumped by one-third to 87.2p. Shareholders would also receive a 3p/share special dividend if the bid goes ahead.

Shareholders would also be given the option to receive a partial loan note alternative with 65% in loan notes and/or preference shares and 35% in cash. There is also an option to reinvest 40% of the cash proceeds in loan notes or preference shares.  

The business is split into four divisions: commercial services, insurance, international and connected services.

History

Back in March 2019, DWF was the first lawyer to float on the Main Market – the rest are on AIM. It raised £75m at 122p/ share, which valued DWF at £366m. After a strong start the share price slumped in 2020 – probably due to the end of the one-year lock-in following flotation – before recovering. However, there has been a downward trend since the beginning of 2022.

Dividends paid since flotation total 15.1p/share. Last year, 4.75p/share was paid.

Zeus trimmed its 2022-23 pre-tax profit forecast by 4% to £44.1m but maintained the following year at £54.2m. Taking the total potential consideration as 100p/share, the prospective 2022-23 multiple is less than ten, falling to nine. That compares with a multiple of 20 when DWF floated.

That rating is higher than for some AIM rivals, such as Knights Group Holdings (LON: KGH), and similar to Gateley (LON: GTLY).  

AIM movers: Helium One buys drilling rig and Totally warns of tough conditions

1

Helium One Global (LON: HE1) has bought an Epiroc Predator 220 drilling rig so that it can start drilling the Tai-C well at the Rukwa site in Tanzania by September. An experienced crew will be required for this. Costs will be higher as they will no longer be shared with Noble. The share price rebounded 41.2% to 7.2p, which more than makes up for the fall at the end of last week.

Knights Group Holdings (LON: KGH) grew revenues by 13% to £142.1m with the growth coming from acquisitions. Management is confident that organic growth will improve thanks to price rises and recruitment of additional fee earners by the legal services company. Pre-tax profit was 19% ahead at £21.6m. Net debt was £29.2m at the end of April 2023 with cash generation covering acquisition and dividend costs. The total dividend was raised 15% to 4.03p/share and it is covered five times by earnings. The share price has slumped by one-third this year due to concerns about the debt level, but this is a highly cash generative business. The share price recovered 9.87% to 70.1p.

Artemis Resources Ltd (LON: ARV) has identified lithium bearing pegmatites within the Osborne joint venture, where it owns 49%. Artemis Resources has tenements adjoining the joint venture area and geochemical soils sampling data indicates elevated lithium levels. A high resolution dipole-dipole induced polarisation geophysics survey has commenced at the Lulu Creek gold prospect. Results of the moving loop electromagnetic survey of the Greater Carlow area are due to be finalised in mid-July. The share price improved 7.5% to 1.075p.

Eco Animal Health (LON: EAH) reported full year figures ahead of expectations. Revenues were 4% higher at £85.3m and pre-tax profit was flat at £3.9m. Net cash was £21.7m at the end of March 2023. Two poultry vaccines are near to submission for approvals. R&D exploration will be increased to £10.4m this year. The new products will reduce the dependence on pig treatment Aivlosin. A 2023-24 pre-tax profit of £4.3m is forecast. The share price is 7.14% higher at 105p.

Totally (LON: TLY) increased full year pre-tax profit from £1.3m to £1.8m but the healthcare services provider warns that this year will be tougher. The total dividend has been cut from 1p/share to 0.625p/share. The main growth is coming from elective care services, where Totally is helping the NHS to reduce waiting lists. The loss of four contracts hit urgent care revenues and a lack of new tenders means that it will be difficult to rebuild them. The share price dipped 22.1% to 13.25p

Petro Matad (LON: MATD) is abandoning the Velociraptor-1 exploration well in Block V of the Taats Basin in Mongolia after it intercepted water-bearing reservoirs. This was always a high risk well, but it reduces Shore’s risked NAV from 14.5p/share to 8p/share. The focus will be Block XX. The share price fell 11.3% to 4.3p.

Scotgold Resources (LON: SGZ) revealed first half production of 2,314 ounces of gold was less than the original plan for 2023. Production rates are improving following the move from cut and fill mining to long hole stoping and grades are improving. The financial position of the company still depends on continued improvements in production and a third-party review of the current mine plan is ongoing. The share price slipped 11.4% to 15.5p.

Currency and payment services provider Argentex (LON: AGFX) increased interim revenues by 28% to £25m with strong growth for the online platform. Nigel Railton is taking over as chair from Lord Digby Jones. Although trading is in line with expectations the share price fell 10.2% to 119.5p.

BT CEO to step down

BT Group CEO Philip Jansen will step down from his role within the next 12 months. BT said they have already begun the succession process.

Jansen has overseen the mammoth task of connecting UK homes to Fibre but growth at a group level has stalled under his tenure.

“Philip Jansen had a massive list of problems to fix the second he walked in the door as the new boss of BT in February 2019,” said Russ Mould, investment director at AJ Bell.

“His decisions were logical: cut more of the fat from the business, sharpen the focus on providing faster broadband to households across the country and find alternatives for non-core operations such as putting the sports broadcasting arm into a joint venture.

“Sadly, Jansen is not going to be remembered for being the person who breathed life back into BT. It’s still the slow, creaking juggernaut today that it was before he joined. Earnings are forecast to go into reverse this financial year and show minimal progress over the following two years.

“Shareholders have suffered big time: more than £10 billion has been wiped off the value of the business under Jansen’s leadership, and BT is now nearly one-quarter owned by a French billionaire who has taken advantage of the weak share price to build a strategic stake.”

Helium One shares soar on drill programme update

Helium One shares surged in early trade on Monday after releasing an update on drilling activities at their Tanzanian Helium assets.

Last week, Helium One said they were becoming frustrated with the lack of action taken by SOFORI after signing a letter of intent to provide a rig to enable drilling to start in Q3 2023. At the time, Helium One said they were exploring other avenues to ensure spudding of the drill holes would commence on schedule.

On Monday, Helium One announced they had acquired their own rig and now had full control over the drilling programme and were no longer reliant on third parties.

“I am pleased to note the above significant progress made with our efforts to ensure we drill our exciting Tai Prospect in Rukwa with a recently upgraded P50 Helium resource of 2.8 Bcf,” said Ian Stalker, Chairman, Helium One.

“This is indeed a milestone event for the Company and opens up a range of ancillary options for the Company as well as, most importantly, securing the control of our own drilling programme and any future appraisal and further exploration activities.”

Helium One has acquired an Epiroc Predator 220 drilling rig capable of drilling to depths in excess of 2,000 metres and signed a separate contract with Baker Hughes for wireline, cementing and fluids services.

Helium One shares were 49% higher at 7.6p at the time of writing.

Is it time to buy Currys?

Mixed results and stopping the dividend pushed the Currys (LON: CURY) share price to new lows last week. The consumer appliances retailer is performing poorly outside of the UK and trading could get tougher.
Currys Chair Ian Dyson acquired 150,000 shares at 47.56p each and finance chief Bruce Marsh bought 65,000 shares at 46.694p each. That shows some confidence because of the significant amount of money spent, but it does not necessarily mean that others should follow suit. The current share price is 49.42p.
Currys reported a 2022-23 loss on a 6% fall in revenues to £9.5bn, but that was down ...

Aquis weekly movers: S-Ventures moving towards profitability

S-Ventures (LON: SVEN) returned from suspension following the publication of full year results and the latest interim figures. They were delayed because of the liquidation of Lizza. Group revenues for the healthy snacks supplier were £7.8m in the year to September 2022. The latest interim revenues were £7.7m, including £800,000 from discontinued activities, but it remains loss-making. However, S-Ventures is currently achieving a positive EBITDA. There was £400,000 in the bank at the end of March 2023. Sales momentum is improving. The share price increased 4.53% to 8,65p.

==========

Fallers

Apollon Formularies (LON: APOL) reported 2022 results after the market closed on 30 June. The share price has slumped 15.6% to 135p. Revenues rose 45% to £286,000, but the medical cannabis company continues to lose money. The company warns that it does not have enough cash for its current requirements, and it will have to raise money through a share issue or by selling assets.

Cadence Minerals (LON: KDNC) shares fell 3.16% to 7.65p during the week. Edison published an initiation note on Thursday. It believes Cadence Minerals is worth 32.2p/share.

Voyager Life (LON: VOY) has ended the deal to acquire the CBD extraction and manufacturing facility in Poland from Goodbody Health. It took longer than expected to gain the approval for the change in ownership. Voyager Life has obtained a manufacturing order from a client and has already supplied another order worth £25,000, which was made in Scotland where the facility is being upgraded. There is £787,000 in cash and that should last 12 months. The £1m of convertible loan notes will not be issued as the acquisition is not going ahead. The share price was 2.22% lower at 11p.

KR1 (LON: KR1) reported an NAV of 55.01p/share at the end of May 2023. The digital assets generated income of £385,000 during May. KR1 is extending its services agreement with Reflexivity and adding a 12 months notice period. Two KR1 directors own Reflexivity. The KR1 share price slipped 0.96% to 51.5p.

Trading in the shares of Eight Capital Partners (LON: ECP) and Marula Mining (LON: MARU) was suspended at the beginning of the week because they have not published 2022 accounts.

AIM weekly movers: Yourgene Health takeover

1

Yourgene Health (LON: YGEN) is recommending a 0.522p/share cash bid from fellow diagnostics company Novacyt (LON: NCYT). This values Yourgene Health at £16.7m. Last December, Yourgene Health raised £6m at 0.3p/share. Novacyt is spending some of the cash it generated during Covid as it seeks to replace those testing revenues. The Yourgene Health share price jumped 151% to 0.49p, while the Novacyt share price also improved 8.36% to 41.175p because of the prospects for the deal.

Accounting software provider Glantus (LON: GLAN) shares have recovered 141% to 20.5p following the confirmation of potential offer discussions with Accel-KKR and investee company Basware Corp.  Finland-based Basware supplies financial automation technologies. Glantus announced 2022 results in the previous week. There was a large loss and management hopes that the first quarter of 2023 could be profitable. Glantus has a poor record since joining AIM in May 2021 at 102p/share. At that time Glantus raised £10m and existing shareholders raised £4m. The market capitalisation is currently £10.5m.

UniVision Engineering Ltd (LON: UVEL) says it is unaware why the share price improved 133% to 0.35p. The CCTV installer returned from suspension on 19 June when interim figures were published, and the share price initially fell to 0.075p before bouncing back. Potential sources of finance are being investigated.

Cleantech investment company i(x) Net Zero (LON: IX.) says investee company WasteFuel Global has secured a $10m investment from BP. This funding increases the valuation of the i(x) Net Zero stake by 181% to $131.7m. The total value of the company’s portfolio has increased from $63.8m to $148.6m. WasteFuel is developing bio-methanol plants. The share price has rebounded 64.3% to 23p. The February 2022 placing price was 76p.

==========

Fallers

Quadrise (LON: QED) has launched a placing and open offer to raise up to £3.2m at 1.25p/share. A placing has already raised £1.1m and an open offer could generate up to £2.2m. The clean energy company will use the cash to fund active projects and additional growth. Parts and spares have been delivered to Morocco and it is ready to recommence the demonstration test that was paused in May. The share price slumped 40.4% to 1.255p.

Zanaga Iron Ore (LON: ZIOC) moved from loss to profit in 2022, but that was down to a $9.1m gain on the revaluation of an investment. Shard Merchant Capital is subscribing for 36 million shares in three equal tranches. Shard Merchant Capital will then attempt to place the subscription shares and pay Zanaga Iron Ore 95% of the gross proceeds. The first tranche has been subscribed for and the next tranche ten days after those shares have been placed. Shard Merchant Capital previously subscribed for 21 million shares. The share price slipped 38.2% to 7.69p.

Restore (LON: RST) chief executive Charles Bligh has stepped down and first half trading has been mixed. Records management remains a steady growth business with the relocation business also trading well. It has been tougher for the technology and shredding operations. Pre-tax profit guidance has been cut from £41m-£43m to £31m. Jamie Hopkins has taken over as interim chief executive. The share price has fell 28.4% to 167.5p.

Ship and renewable infrastructure builders Harland & Wolff (LON: HARL) reported its 2022 figures after the market closed on 30 June. The reported loss is £70.4m on revenues of £28m. There was a £6.39m charge for discontinued contracts. The contracted backlog is around £900m. Management is hopeful that a refinancing can be secured by the autumn. This should last for five years. The share price declined 27.5% to 9.25p.

Potential new lithium project investment

1

Medcaw Investments (LON: MCI) is considering acquiring a company with a lithium project in Southern Ethiopia. This is a change to the original plan for the standard list shell, which was going to acquire a life sciences business.

Abyssinian Metals Ltd (AML) has a 51% stake in the Kenticha lithium caesium tantalum project with the other 49% owned by the Oromia state. The project has a JORC, open-pit, inferred resource of 87.7mt at 0.78% Li2O with upside of up to 51mt. The grade could increase to up to 25%. Three higher grade starter pits have been identified.

Stage one is planned for 80,000tpa of 5.5% spodumene concentrate from a plant due to be commissioned by the end of 2023. A second plant is planned for the end of 2024. By 2025, it is estimated that annualised revenues could be $720m, assuming a sales price of $3,000/t and all in sustaining costs of $750/t.

AML already has a credit facility of $25m. The company has 100% of the marketing rights of production.  

Due diligence will commence, and the two companies will work together to agree a potential offer for 100% of AML. The acquisition will be conditional on at least 51% acceptances.   

Medcaw Investments raised £400,000 at 8p/share prior to trading in the shares being suspended. There was cash of £644,000 at the end of 2022. More cash will be required to finance the acquisition (although that could be via a share swap) and/or bringing the project into production.